Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Accumulated Expenses (2016 - 2026)

Tenax Therapeutics' Accumulated Expenses history spans 7 years, with the latest figure at $363306.0 for Q4 2017.

  • On a quarterly basis, Accumulated Expenses fell 93.07% to $363306.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $363306.0, a 93.07% decrease, with the full-year FY2017 number at $363306.0, down 93.07% from a year prior.
  • Accumulated Expenses hit $363306.0 in Q4 2017 for Tenax Therapeutics, up from $223088.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for TENX hit a ceiling of $5.2 million in Q4 2016 and a floor of $46393.0 in Q1 2015.
  • Historically, Accumulated Expenses has averaged $1.3 million across 5 years, with a median of $612822.0 in 2014.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 1187.87% in 2014 and later plummeted 98.18% in 2017.
  • Tracing TENX's Accumulated Expenses over 5 years: stood at $322443.0 in 2013, then skyrocketed by 304.44% to $1.3 million in 2014, then crashed by 58.15% to $545715.0 in 2015, then surged by 861.22% to $5.2 million in 2016, then tumbled by 93.07% to $363306.0 in 2017.
  • Business Quant data shows Accumulated Expenses for TENX at $363306.0 in Q4 2017, $223088.0 in Q3 2017, and $1.7 million in Q2 2017.